UBS Group Begins Coverage on Cyclerion Therapeutics (NASDAQ:KRSA)

Analysts at UBS Group assumed coverage on shares of Cyclerion Therapeutics (NASDAQ:KRSA) in a report issued on Friday, Benzinga reports. The brokerage set a “buy” rating and a $55.00 price target on the stock.

Separately, Zacks Research upgraded shares of Cyclerion Therapeutics to a “hold” rating in a research note on Wednesday. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Cyclerion Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $55.00.

Cyclerion Therapeutics Trading Down 100.0%

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases of the central nervous system. The company has concentrated on therapies designed to influence the nitric oxide–soluble guanylate cyclase signaling pathway, which may play a role in neurological and other debilitating conditions.

Cyclerion’s lead development program was IW-6463, an oral, central nervous system-penetrant soluble guanylate cyclase stimulator investigated for potential use in neurodegenerative diseases, including Alzheimer’s disease and amyotrophic lateral sclerosis.